» Articles » PMID: 28931091

T-cell Responses Targeting HIV Nef Uniquely Correlate with Infected Cell Frequencies After Long-term Antiretroviral Therapy

Abstract

HIV-specific CD8+ T-cell responses limit viral replication in untreated infection. After the initiation of antiretroviral therapy (ART), these responses decay and the infected cell population that remains is commonly considered to be invisible to T-cells. We hypothesized that HIV antigen recognition may persist in ART-treated individuals due to low-level or episodic protein expression. We posited that if persistent recognition were occurring it would be preferentially directed against the early HIV gene products Nef, Tat, and Rev as compared to late gene products, such as Gag, Pol, and Env, which have higher barriers to expression. Using a primary cell model of latency, we observed that a Nef-specific CD8+ T-cell clone exhibited low-level recognition of infected cells prior to reactivation and robust recognition shortly thereafter. A Gag-specific CD8+ T-cell clone failed to recognized infected cells under these conditions, corresponding with a lack of detectable Gag expression. We measured HIV-specific T-cell responses in 96 individuals who had been suppressed on ART for a median of 7 years, and observed a significant, direct correlation between cell-associated HIV DNA levels and magnitudes of IFN-γ-producing Nef/Tat/Rev-specific T-cell responses. This correlation was confirmed in an independent cohort (n = 18). Correlations were not detected between measures of HIV persistence and T-cell responses to other HIV antigens. The correlation with Nef/Tat/Rev-specific T-cells was attributable to Nef-specific responses, the breadth of which also correlated with HIV DNA levels. These results suggest that ongoing Nef expression in ART-treated individuals drives preferential maintenance and/or expansion of T-cells reactive to this protein, implying sensing of infected cells by the immune system. The direct correlation, however, suggests that recognition does not result in efficient elimination of infected cells. These results raise the possibility that enhancing the cytolytic activity of Nef-specific T-cells may lead to reductions in infected cell frequencies, even in the absence of therapeutic latency reversal.

Citing Articles

HIV-SEQ REVEALS GLOBAL HOST GENE EXPRESSION DIFFERENCES BETWEEN HIV-TRANSCRIBING CELLS FROM VIREMIC AND SUPPRESSED PEOPLE WITH HIV.

Frouard J, Telwatte S, Luo X, Elphick N, Thomas R, Arneson D bioRxiv. 2025; .

PMID: 39763963 PMC: 11702770. DOI: 10.1101/2024.12.17.629023.


Recognition of HIV-1-infected fibrocytes lacking Nef-mediated HLA-B downregulation by HIV-1-specific T cells.

Kuse N, Noyori O, Takahashi N, Zhang Y, Suzu S, Takiguchi M J Virol. 2024; 98(7):e0079124.

PMID: 38940584 PMC: 11264601. DOI: 10.1128/jvi.00791-24.


Persistence of a Skewed Repertoire of NK Cells in People with HIV-1 on Long-Term Antiretroviral Therapy.

Anderko R, DePuyt A, Bronson R, Bullotta A, Aga E, Bosch R J Immunol. 2024; 212(10):1564-1578.

PMID: 38551350 PMC: 11073922. DOI: 10.4049/jimmunol.2300672.


Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.

Crowell T, Ritz J, Zheng L, Naqvi A, Cyktor J, Puleo J AIDS. 2024; 38(8):1141-1152.

PMID: 38489580 PMC: 11323228. DOI: 10.1097/QAD.0000000000003881.


Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure.

Armani-Tourret M, Bone B, Tan T, Sun W, Bellefroid M, Struyve T Nat Rev Microbiol. 2024; 22(6):328-344.

PMID: 38337034 PMC: 11131351. DOI: 10.1038/s41579-024-01010-8.


References
1.
Rosen C, Sodroski J, Goh W, Dayton A, Lippke J, Haseltine W . Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature. 1986; 319(6054):555-9. DOI: 10.1038/319555a0. View

2.
Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

3.
Lee S, Bacchetti P, Chomont N, Fromentin R, Lewin S, ODoherty U . Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. PLoS One. 2016; 11(8):e0160192. PMC: 4970722. DOI: 10.1371/journal.pone.0160192. View

4.
Adams M, Wong C, Wang D, Romeo J . Limitation of Tat-associated transcriptional processivity in HIV-infected PBMC. Virology. 1999; 257(2):397-405. DOI: 10.1006/viro.1999.9647. View

5.
Cartwright E, Spicer L, Smith S, Lee D, Fast R, Paganini S . CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. Immunity. 2016; 45(3):656-668. PMC: 5087330. DOI: 10.1016/j.immuni.2016.08.018. View